Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
Merck's combination of a wide lineup of high-margin drugs and a pipeline of new drugs should ensure strong returns on invested capital over the long term. Further, following the divestment of the ...
Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...
Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.
Key considerations for patent counsel when evaluating potential conflicts of interest, including identifying conflicts between current and former clients, understanding relevant authority, navigating ...
Co., Inc. (NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial ...
When Merck reports fourth-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, ...
These are unquestionably serious issues, but Merck remains a top stock to buy and hold, at least for investors focused on the long game. Here's why. Merck's Keytruda generates over $20 billion in ...
Recent developments in Merck's pipeline have ... patents expire, remains a concern for investors. Without a clear succession plan for Keytruda, Merck risks losing ground to competitors with newer, ...
How many years did it take for Dennis Rodman to ... Dennis Rodman and more: 5 NBA players who have been arrested for driving under the influence Scottie Pippen, Dennis Rodman and more: 5 NBA ...